Vascular endothelial growth factor (VEGF)-initiated angiogenesis requires coordinated proteolytic degradation of extracellular matrix provided by the urokinase plasminogen activator/urokinase receptor (uPA/uPAR) system and regulation of cell migration provided by integrin-matrix interaction. In this study, we investigated the mechanisms underlying the uPAR-dependent modulation of VEGF-induced endothelial migration.
Introduction
Angiogenesis 1 is crucial not only during embryonic development and repair of tissue damage. Tumour cells also recruit endothelial cells to sprout new blood vessels, which support their expansive growth. Vascular endothelial growth factor (VEGF) is the key angiogenic growth factor, because it regulates all steps required for angiogenesis, i.e. induces endothelial cell proliferation and migration, increases vascular permeability, and allows for expression of active proteases on the cell surface. 2 As a consequence, matrix molecules are degraded and a new provisional extracellular matrix (ECM) is created that promotes invasion of the surrounding tissue by endothelial cells. The glycosylphosphatidylinositol (GPI)-anchored urokinase receptor (uPAR), a specific receptor for the serine protease urokinase plasminogen activator (uPA), also contributes to ECM remodelling by focusing proteolytic activity on the surface of invading cells. 3 In addition, the uPAR system also regulates endothelial cell survival 4 and is itself tightly regulated by cell density. 5 A link to VEGF- † These authors contributed equally to the manuscript. ‡ Deceased on 28 August 2010.
controlled signalling pathways is evident; activation of pro-uPA and uPAR redistributions to focal adhesions are essential steps in VEGF-induced endothelial cell migration in vitro and in vivo. 6, 7 Cell migration is contingent on the regulated activation and inactivation of adhesion receptors. Integrins must disengage from ECM contacts at the trailing end and form new focal contacts at the leading edge. This requires continuous and vectorial integrin redistribution. The b1-integrin subfamily is essential for early angiogenesis; a deletion of b1 in vascular endothelial cells is embryonically lethal and causes defects in angiogenic sprouting and vessel branching. 8 Integrin ligation with their matrix ligands triggers intracellular signalling via an interaction with molecules that regulate the organization of the actin cytoskeleton. Integrins undergo a transition from a latent form that does not recognize cognate ligands to a binding-competent conformation; uPAR is among the proteins that can impinge on this switch by interacting with integrins of the b2 and of the b1 subfamily. 9, 10 We have previously shown that the migratory response of endothelial cells to VEGF depends on the uPAR. 7 This was observed on vitronectin-an ECM protein which is a ligand for the uPAR. 11 This observation suggested that VEGF relied-at least in part-on uPAR to induce endothelial migration. Here, we addressed the question, whether uPAR was necessary for VEGF-induced endothelial migration on fibronectin and other typical ECM components that are not ligands for uPAR. We show that uPAR mediates a5b1-integrin internalization upon VEGF stimulation of endothelial cells. This intracellular sequestration of integrins occurred via clathrin-coated vesicles and was also dependent on low-density lipoprotein receptor (LDL-R) family members. Blocking the association of uPAR and integrins did not only affect integrin redistribution, but also impaired VEGF-stimulated endothelial cell migration in vitro and in vivo. Thus, in addition to its central role in matrix proteolysis, uPAR is also crucial for integrin redistribution that is necessary to support angiogenesis.
Methods

Materials
The sources of all materials are listed in the Supplementary material online.
Cell culture
Human umbilical vein endothelial cells (HUVECs) (Technoclone) and murine microvascular endothelial cells were cultured in M199 and Dulbecco modified Eagle medium, respectively, supplemented with 20% foetal calf serum, 22.5 mg/mL heparin, and 3 mg/mL bovine endothelial cell growth supplement. Murine microvascular endothelial cells were isolated from the uterus of uPAR-deficient mice and wild-type littermate controls. Mice were sacrificed by cervical dislocation and pieces of the uteri lacking visible fat tissue were enzymatically treated by a mixture consisting of collagenase A, dispase, and DNase. Subsequently, microvascular endothelial cells were selected using Dynabeads coupled to anti-CD31 antibody and Dynal MPC Magnetic Particle Concentrator (Dynal Biotec). Experiments were performed using quiescent subconfluent cultures up to passage 5. Cells were rendered quiescent by serum withdrawal (24 h 5% FCS, 4 h serum-free M199 containing 1% BSA).
Flow cytofluorometry
Subconfluent endothelial cells were treated as indicated with growth factors (VEGF 165 , VEGF-E) for the appropriate time. Following stimulation, the cells were washed with ice-cold PBS, harvested with 3 mM EDTA, and fixed with 4% paraformaldehyde for 15 min. In some instances, a parallel culture was permeabilized with 0.2% Triton X-100 for 10 min. After blocking with 2% goat serum, the appropriate primary antibody was added for 60 min at room temperature. Following a PBS wash, the samples were incubated with the appropriate Alexa Fluor 488-conjugated secondary antibody, washed and analysed with FACSort (BectonDickinson). In the case of experiments using inhibitors or peptides, the cells were pre-treated with the appropriate amounts for 10 min prior to stimulation. For the siRNA experiments, HUVECs were transfected with uPAR siRNA (100 nM) using X-tremeGENE siRNA transfection reagent according the manufacturer's instructions. After 36 h, cells were stimulated with VEGF and analysed as earlier.
Surface biotinylation and immunoblotting
HUVECs were washed with ice-cold PBS (pH 8.0) and incubated with 2 mM sulfo-NHS-LC-biotin for 30 min on ice, either before or after VEGF stimulation. Following a wash in ice-cold glycine (200 mM, in PBS, pH 7.0) to remove excess biotin, the samples were lysed in a RIPA buffer for 30 min on ice. The biotinylated surface proteins were adsorbed by overnight incubation with streptavidin-coated Sepharose 4B beads. The beads were washed three times with the RIPA buffer and the adsorbed material eluted by boiling in non-reducing sample buffer. Proteins were separated on SDS polyacrylamide gels, transferred to PVDF membrane and probed with relevant antibodies. Immunoreactive bands were detected by enhanced chemiluminescence.
Immunocytochemistry
The samples were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100 for 5 min, and blocked with 5% goat serum for 1 h at room temperature. Samples were stained with the specific primary antibodies for 2 h at 378C. After washing and incubation with the appropriate secondary antibodies for 2 h at 378C, samples were mounted in Vectashield and visualized on an Olympus AX70 microscope or a Zeiss LSM510.
Micropatterning
The micropatterning experiment was performed as previously described 12 with the following modifications. Polydimethylsiloxane stamps containing the microarray were generated by the standard photolithography. Stamps were rinsed with 100% ethanol and water, dried under N 2 , and incubated with 100 mg/mL Cy5-labelled BSA for 30 min at room temperature. The stamps were washed and dried as before and placed under their own weight onto epoxy-derivatized glass coverslips for 1 h. Upon removing the stamps, the coverslips were sealed with adhesive silicone masks. The glass coverslips that were coated with a Cy5-labelled BSA micropattern were then incubated with 50 mg/mL of streptavidin and incubated with 10 mg/mL biotinylated monoclonal antibody. Endothelial cells were seeded on micropatterns and allowed to adhere. Following stimulation, samples were fixed with 4% paraformaldehyde. They were stained for uPAR with the monoclonal mouse 3937 antibody (pre-labelled with Alexa Fluor 488-conjugated Fab fragments) for 60 min. Images were acquired on a Axiovert 200/M microscope (Zeiss) in the total internal reflection configuration using oil immersion (objective magnification ¼ 100-fold). Images were analysed using a semi-automated image and data analysis software that was developed in-house; an automatic gridding algorithm calculates the grid size and the rotation angle w of the image. The grid subdivides the total image into adjacent squares, which are quantified according to the average specific signal with a central circle (F + ) and unspecific background outside the circle (F 2 ). This information is used to calculate fluorescence (F) and contrast (C). R.A. Alexander et al.
Migration assay
For the Transwell TM migration assay, serum-starved HUVECs (25 000) treated with or without the inhibitory peptides (25 mM) were seeded on 8 mm pore Transwell TM inserts coated with 5 mg/mL fibronectin. After 4 h, the cells that had not migrated were removed from the upper chamber. Migrated cells were fixed with 4% paraformaldehyde, stained with Hoechst (DAPI) 1:1000 for 15 min and counted using a 10× objective of an Olympus AX70 microscope.
In vivo angiogenesis
A subcutaneously deposited matrigel plug was used to assess angiogenesis in vivo as previously described. 7 Briefly, mice were anaesthetized with ketamin (100 mg/kg) and xylazin (10 mg/kg); when mice did not react to pinching, growth factor-depleted matrigel solution (0. 
Statistics
Statistical significance was assessed by using Student's t-test for paired observations. Multiple comparisons were done by ANOVA and Dunnett's post hoc test.
Results
VEGF induces internalization of b 1 -integrins
In VEGF-induced sprouting of capillaries, endothelial cells must reorganize their contacts with the ECM. We focused on the b1 subfamily of integrins, because members of this subfamily are considered to be the adhesion molecules utilized in the unstimulated, resting state of endothelial cells. 13 VEGF 165 stimulation of quiescent endothelial cells resulted in a marked redistribution of b1-integrins. In resting endothelial cells, the b1-integrin subunit was found mainly at the cell periphery: the immunoreactivity outlined the cell borders ( Figure 1A , control). In contrast, in VEGF 165 -stimulated endothelial cells immunostaining at the cell borders declined and increased in the vicinity of the nuclei ( Figure 1A , VEGF). This shift suggested that VEGF caused internalization of integrins. We confirmed this internalization by assessing the amount of b1-integrins at the cell surface before and after VEGF stimulation on non-permeabilized cells. In parallel, permeabilized cells were assessed for changes in the total cellular amount of the b1-integrin subunit. As shown in Figure 1B and Supplementary material online, Figure S1 , VEGF 165 stimulation of endothelial cells resulted in an 30% decrease in the amount of b1-integrins at the cell surface (non-permeabilized cells, red histograms). VEGF did not affect the total amount of b1-integrins (permeabilized cells, black histograms). In addition, we confirmed the internalization of b1-integrins by cell surface biotinylation of endothelial cells ( Figure 1C ). If cell surface proteins were biotinylated prior to VEGF 165 stimulation, the amount of biotinylated b1-integrins recovered from the whole cell lysates did not differ between stimulated and unstimulated cells ( Figure 1C , right-hand lanes). However, if cells were subjected to biotinylation after they had been exposed to VEGF, we observed a decline (by 30 -40%) of biotinylated b1-integrins when compared with unstimulated cells. Thus, both approaches provided incontrovertible evidence for VEGF-induced internalization of b1-integrins in endothelial cells.
uPAR and b1-integrins interact and co-internalize upon VEGF stimulation
We previously observed that, within a similar time interval, VEGF also caused internalization of the uPAR. 8 We therefore explored if uPAR and b1-integrins co-clustered and co-internalized upon VEGF stimulation. This was the case: in unstimulated endothelial cells, b1-integrins were mainly found at the cellular periphery, b3-integrins in the perinuclear compartment, and uPAR was distributed in a distinct but diffuse pattern ( Figure 2A , control). Treatment with VEGF 165 led to the redistribution of uPAR to the newly formed focal adhesions, where it co-localized with b3-integrins. Finally, treatment with VEGF reduced co-locolization of integrin subunit b1 with pFAK but augmented that with uPAR in vesicular structures (Supplementary material online, Figure S3 ). These observations confirmed co-internalization of b1-integrins and uPAR into the same endocytotic vesicles (Figure 2A , VEGF). The addition of VEGF also induced co-localization of uPAR and b1 integrins in polarized cells, which had migrated into the cell-free area created by scratching the endothelial monolayer, (Supplementary material online, Figure S6 ). Integrin and uPAR redistribution was not observed, if endothelial cells were incubated with RAP prior to stimulation with VEGF ( Figure 2A , VEGF/RAP). RAP precludes complex formation between uPAR and LDL-R family-like proteins and their internalization. 8, 14 This indicated that an LDL-R-like protein mediated the co-internalization of uPAR and b1-integrins. We used micropatterning as an independent approach to demonstrate the interaction between uPAR and integrins in VEGF-stimulated endothelial cells. The micropatterning technique was recently introduced as a method to assess protein-protein interactions on the surface of living cells. 12 It relies on the immobilization of a given antibody in a geometric pattern on a glass coverslip. We used an antibody to the b1-integrin subunit. Accordingly, on attaching and spreading cells b1-integrins were captured at these spots of immobilized antibody (not shown). In unstimulated cells, uPAR was distributed homogeneously with occasional punctuate staining ( Figure 2Ba ). In contrast, upon VEGF stimulation of endothelial cells uPAR was redistributed to the pattern defined by the immobilized integrin antibody (Figure 2Bc) . The quantitative analysis for the single spot fluorescence yielded a mean contrast of 0.35 ( Figure 2Bd ) for stimulated cells and a mean contrast of 0.07 for unstimulated cells (Figure 3Bb ). This high mean contrast between areas of antibody spots and the background BSA grid provides a quantitative readout and documents that VEGF caused uPAR to become enriched in areas of immobilized integrins. In contrast, if an activating antibody against integrin subunit b1 was used as bait, we did not observe any association between uPAR and b1-integrins upon VEGF stimulation ( Figure 2C ). These observations and earlier findings 6 are consistent with the notion that integrins uPAR-mediated integrin internalization upon VEGF stimulation need to be in their inactive state to allow for VEGF-induced complex formation with uPAR. Stimulation of VEGFR-2 triggers several signalling pathways [e.g. phospholipase C-g-mediated protein kinase C activation, RASdependent ERK activation, stimulation of Src kinase (SRC), etc]. We recently observed that activation of a receptor tyrosine kinase and of LRP-1 in the presence of uPAR resulted in sustained ERK activation and increased cellular adhesion. 15 VEGF-induced uPAR internalization via a signalling pathway comprising VEGFR-2, PI3-kinase and matrix metalloproteinase (MMP-2). 6 Accordingly, we interrogated the signalling network underlying integrin internalization by using several inhibitors, i.e. the PI3-kinase inhibitor wortmannin, the MMP-2/9 inhibitor (2R)-2-[(4-biphenylylsulfonyl)amino]-3-phenylpropionic acid, the MEK1-inhibitor PD98050 (to block activation of ERK1/2), the inhibitor of PLC-g U73122 and PP1 to suppress the non-receptor tyrosine kinase SRC. Serum-starved endothelial cells were pre-treated with these inhibitors and stimulated with VEGF-E, the specific ligand for VEGFR-2 and with PlGF, the specific ligand for VEGFR-1. Flow cytometry showed that VEGF-E-induced but not PlGF-induced internalization of b1-integrins was blunted upon inhibition of PI3-kinase and MMP-2/9 inhibitor ( Figure 2D ). In contrast, neither VEGF-E-nor PlGF-stimulated internalization of uPAR or integrins was inhibited by inhibition of ERK1/2, SRC, or PLC (not shown). Taken together, our results show that internalization of b1-integrins is controlled by the same pathway (i.e. VEGFR-2 and PI3-kinase-dependent activation of MMP-2) as recycling of uPAR.
The presence of uPAR is essential for VEGF-induced internalization of b1-integrins into clathrin-coated vesicles
The uPAR is internalized in a trimeric uPAR/uPA/PAI-1 complex via clathrin-coated vesicles in response to addition of the uPA:PAI-1 complex.
14 If uPAR and b1-integrins are co-internalized, b1-integrins Cell surface proteins were biotinylated either before or after VEGF 165 stimulation for 60 min and enriched by affinity precipitation on streptavidin beads from detergent extracts; biotinylated uPAR and b1-integrins was detected by immunoblotting and quantified by densitometry relative to the unstimulated control, which was the 100% reference value. Immunoblotting with an antiserum recognizing all G protein b-subunits was done as a loading control. Mean + standard deviation (n ¼ 3), **P , 0.01, t-test for paired data.
must also be found in clathrin-coated vesicles. Upon VEGF 165 stimulation of HUVECs, b1-integrins co-localized with the clathrin heavy chain ( Figure 3A , VEGF) in vesicle-like structures. The clathrinmediated internalization of integrins and the concomitant internalization of uPAR may happen by co-incidence. Alternatively, complex formation may be required to drive efficient endocytosis of integrins. We employed two different approaches to discriminate between these two possibilities. In the first approach, endothelial cells were pre-treated with phosphatidylinositol-specific phospholipase C (PI-PLC) to cleave off all GPI-anchored proteins including uPAR from the cell surface. They were then stimulated with VEGF-E; surface integrin levels were subsequently assessed by flow cytofluorometry. The lack of uPAR impaired VEGF-induced internalization of b1-integrins ( Figure 3B ).
Our second approach relied on confocal microscopy. Murine endothelial cells lacking the uPAR were analysed for their ability to redistribute integrins to clathrin-coated structures upon stimulation with mVEGF 164 . In wild-type mouse endothelial cells mVEGF 164 induced a significant, albeit small ( 20%) increase in the co-localization of b1-integrins and clathrin ( Figure 3C ). As expected, this increase in co-localization was inhibited by pre-treatment with RAP. In uPAR 2/2 murine endothelial cells, no increase in the co-localization of clathrin and b1-integrins was detectable upon mVEGF 164 stimulation. Similarly, pre-treatment with RAP before mVEGF 164 stimulation did not cause any change in the extent of co-localization. These data indicate that VEGF-induced integrin internalization is dependent on the presence and co-internalization with uPAR to reach clathrincoated vesicles. HUVECs pre-treated with wortmannin (0.1 mM; PI3-kinase inhibitor) or MMP2/9 inhibitor (1 mM) were stimulated with either VEGF-E or PIGF.
(50 ng/mL, each). The surface levels of b1-integrins were determined by flow cytometry as in Figure 1B .
uPAR-mediated integrin internalization upon VEGF stimulation
Integrin-a5b1 associates with uPAR for VEGF-induced endocytosis
At least six different b1-integrin heterodimers have been identified on endothelial cells. 13 We analysed the VEGF-induced change in surface localization of these different a-integrin subunits (not shown). These experiments revealed that a3b1-and a5b1-integrins were internalized upon VEGF 165 stimulation. We examined whether a5b1 or a3b1 interact with uPAR upon VEGF stimulation by employing the micropatterning approach. Micro-biochip surfaces were functionalized with an antibody to either integrin subunit. This forced the a3b1-or a5b1-integrins on adhering cells to accumulate according to the pattern of the immobilized antibody. In the case of VEGF-stimulated cells, uPAR accumulated in the spots of immobilized integrin a5b1 (Figure 4Ab ). This can only be accounted for by a VEGF-induced interaction between uPAR and a5b1. The patterned antibody to integrin a5b1 did not cause any patterning of uPAR upon VEGF stimulation, indicating no appreciable interaction (Figure 4Bb) . Different amino acid residues in domain-3 have been implicated in the interaction of uPAR with b1-integrins. We synthesized peptide 243-251 which contains two implicated residues S245 and H249 16, 17 to define the region within uPAR that provides the necessary interaction needed for integrin internalization. We assessed whether the HUVECs were treated with 5 U/mL of PI-PLC for 15 min and stimulated with VEGF-E (50 ng/mL) for 60 min. Cell surface levels of b1-integrins were determined as in Figure 1B ; (n ¼ 3), mean + standard deviation, **P , 0.01 vs. control, t-test for paired data. (C) VEGF-induced co-localization of b1-integrins and clathrin is absent in uPAR 2/2 murine endothelium. Endothelial cells isolated from the pulmonary microvasculature were preincubated in the absence and presence of RAP (200 nM) for 15 min, stimulated with murine VEGF 164 (50 ng/mL), fixed and permeablized. Immunostaining for clathrin heavy chain (green) and b1-integrins (red) was visualized by confocal microscopy and their co-localization (arrows) quantified by the ImageJ software, which is summarized in the bar diagram; mean + standard deviation (n ¼ 8). **P , 0.05 (ANOVA). Scale bar ¼ 6 mm.
internalization of a5b1 was dependent on uPAR by using this inhibitory peptide. Analysis of surface expression of a5b1 and a3b1 by FACS shows that addition of VEGF 165 led to internalization of 25 and 35% of integrin a3b1 and a5b1, respectively. Pre-treatment with the peptide inhibited the VEGF-induced internalization of a5b1 ( Figure 5A , for the concentration -response curve, see Supplementary material online, Figure S5 ) but not that of a3b1 ( Figure 5B ). In contrast, the scrambled peptide did not have any inhibitory effect ( Figure 5A and B). The peptides did not affect the VEGF-induced internalization of uPAR ( Figure 5C ) indicating that the requirements for co-internalization were asymmetrical; internalization of integrin a5b1 was contingent on complex formation with uPAR, but VEGF-driven endocytosis of uPAR did not require an interaction with integrin-a5b1. As an additional proof of concept, knock-down of uPAR by siRNA also blocked VEGF-induced internalization of the fibronectin receptor a5b1, ( Figure 5D and Supplementary material online, Figure S5 ). RAP is known to inhibit VEGF-induced internalization of uPAR. 7 Thus, RAP is predicted to inhibit the internalization of both, uPAR and integrin-a5b1, if the complex assembles in a hierarchical order. Pre-treatment of endothelial cells with RAP indeed inhibited the internalization of a5b1 ( Figure 5E ). As expected, this was not the case for a3b1 ( Figure 5F ). Taken together, these data are consistent with the VEGF-driven assembly of a complex comprising integrin-a5b1, uPAR, and an LDLR-like protein that is required for the internalization of a5b1.
VEGF-induced endothelial cell migration requires internalization of the uPAR-integrin complex
Integrin-a5b1 is a fibronectin receptor and fibronectin is an essential component of the provisional ECM generated during wound healing and angiogenesis, 13 but it is not a ligand for the uPAR. However, in our model blockage of uPAR recycling is predicted to impair migration because efficient integrin recycling is contingent on the co-internalization of uPAR, integrins, and LDLR-like protein. We therefore examined whether the uPAR inhibitory peptide (which precluded uPAR -integrin interaction) and RAP (which precluded LDLR-like protein-mediated uPAR-integrin internalization) suppressed VEGF-induced migration of endothelial cells on fibronectin. This was the case. In a modified Boyden chamber chemotaxis assay, the inhibitory peptide ( Figure 6A ) and RAP ( Figure 6B ) significantly reduced migration towards VEGF. In contrast, the scrambled peptide did not have any appreciable effect ( Figure 6A ). This also predicts that inhibition of uPAR-mediated integrin recycling must have an effect on endothelial cell migration in vivo. This prediction was verified by subcutaneous injection of control matrigel suspensions or of matrigel containing mVEGF 164 or the combination of mVEGF 164 and RAP. VEGF provides the chemo-attractant stimulus for endothelial cells, which invade the matrigel, deposit additional ECM including fibronectin, and form blood vessels. We compared endothelial invasion into an mVEGF 164 -containing matrigel plug in wild-type mice ( Figure 6C , top) and uPAR 2/2 ( Figure 6C , bottom). Consistent with previous results, 7 the presence of mVEGF 164 promoted the invasion of the matrigel plug and the appearance of vessel-like structures within the matrigel (Figure 6Cb ). This was suppressed by the concomitant presence of RAP in the matrigel plug (Figure 6Cc ). In uPAR 2/2 mice, mVEGF 164 had only a very modest effect on cell invasion (Figure 6Ce ) and this was not affected by RAP (Figure 6Cf ). We used a second approach to inhibit uPAR-mediated integrin recycling and thus endothelial migration and angiogenesis in vivo; we investigated the anti-angiogenic effect of the uPAR-derived peptide m.P243-251 in a DIVAA. The peptide m.P243-251 'TASWCQGSH' corresponds to the domain-3 peptide of human uPAR ( Figure 5A ). Angioreactors filled with basement membrane extract containing either mVEGF or the combination of mVEGF and m.P243-251 were subcutaneously implanted for 11 days in the dorsal flanks of wild-type mice. As predicted, capillary tubes formed in reactors containing mVEGF. In contrast, angiogenesis was significantly inhibited in reactors filled with VEGF and the inhibitory peptide m.P243-251 (Figure 6Da) . The presence of endothelial cells was verified by immunostaining sections from the reactors for CD31 (Figure 6Db and c) . These observations are consistent with the interpretation that uPAR-mediated integrin internalization is a necessary step in VEGF-induced cell migration and invasion.
Discussion
VEGF-directed reprogramming shifts endothelial cells from quiescence to an activated state that enables invasion of the surrounding tissue. Invasion is supported by the redistribution of uPAR to the leading edge of endothelial cells, which results in focused proteolysis of the ECM. 7 This is achieved by complex formation between the GPI-anchored uPAR and a member of the LDL-receptor family and the subsequent internalization of the complex. 14 VEGF drives this endosomal recycling of uPAR by a signalling cascade that emanates from the VEGF-receptor-2/Flk1. 7 Our current observations document that the VEGF signal is funnelled through uPAR to control a second, integrin-dependent limb of the angiogenic response. VEGF-induced recycling of the integrin a5b1 uPAR and is contingent on the clathrin-dependent internalization of a complex that contains an LDLR-like protein. This conclusion is based on the following findings: (i) VEGF promoted assembly of a complex comprising integrin a5b1.
(ii) The internalization of the complex into the same intracellular compartment, namely endosomes that were also decorated with clathrin immunoreactivity was mediated by LDLR-like protein.
(iii) In the absence of uPAR, VEGF failed to trigger internalization of uPAR-mediated integrin internalization upon VEGF stimulation integrin a5b1 and thus initiate the redistributive cycle of integrin endocytosis and exocytosis. This translated into impaired endothelial cell migration in vitro and reduced endothelial cell invasion and vessel formation in vivo.
Earlier experiments suggested a functional interaction of integrin a5b1 and uPAR: upon increasing expression of uPAR, integrin a5b1 was recovered in the immunoprecipitate and this correlated with persistent ERK1/2 activation and enhanced tumour growth in vivo. 18 We employed a micropatterning approach that allowed for direct visualization of VEGF-promoted formation of a complex between uPAR and integrin a5b1 on the endothelial cell surface. The fact that integrin internalization is precluded in this experimental set-up did not only facilitate quantitative assessment of uPAR recruitment but also afforded the unequivocal demonstration that the interaction happened indeed at the cell surface. This new approach does not differentiate whether there is a direct interaction between uPAR and integrins or whether additional proteins-other than LDLR-like proteins-must be recruited to stabilize and internalize the complex. In fact, purified uPAR and purified integrin a5b1 can directly interact in detergent solution. 16 However, our observations
show that in the cell membrane the interaction is subject to regulation. VEGF may either promote a conformational change that increases the mutual affinity of the partners or drive the association by recruiting an additional molecule into the complex. This is underscored by the fact that the activating antibody to integrin a5b1 19 inhibited the VEGF-induced recruitment of uPAR in the micropatterning experiment. In endothelial cells, VEGF triggered endocytosis of integrin a3b1. Previous experiments documented that the binding of integrin a3b1 to uPAR occurred in a uPA-dependent manner. 20 The direct binding of purified uPAR to purified integrin a3b1 and the recovery of uPAR in complex with integrin-a3b1 is contingent on the presence of uPA. 20, 21 Surprisingly, micropatterning did not detect any direct interaction of integrin a3b1 with uPAR. In our opinion, micropatterning is among the most sensitive methods to record interactions in the native cell membrane, because it does not require any modification of the interacting molecules (e.g. by attaching fluorescent moieties) or any change in their stoichiometry (e.g. by heterologous expression). Thus, we conclude that, in endothelial cells, VEGF does not promote complex formation between integrin-a3b1 and uPAR. This conclusion is also supported by the observation that VEGFtriggered endocytosis of integrin a3b1 was not impaired by RAP. The discrepancy between our findings and results from earlier studies 20, 21 is most likely accounted for by cell type-dependent differences. In fact, uPAR can recruit various integrins 9, 16, 20 in a cell typedependent manner. This also supports the conjecture that these complexes are stabilized by the recruitment of additional proteins.
Our observations support a model, where the VEGF-induced signal is propagated via uPAR to reduce integrin a3b1-mediated endothelial adhesion. While the VEGF-induced surface localization of integrin-avb3 is predicted to enhance adhesion, the increase in the turnover of a5b1 reduces adhesion and fosters endothelial cell migration. This predicts that the absence of integrin-a5b1 ought to suppress tumour angiogenesis. In fact, blockage of integrin a5b1 by an antibody suppressed angiogenesis in a murine tumour model, where human rhabdomyosarcoma cells were xenografted into immunodeficient mice. 22 Accordingly, integrin-a5b1 is being explored as a potential target in advanced human cancer; the pertinent chimeric antibody, is currently in phase II clinical trials. 23 The binding sites for integrin-a5b1 are thought to reside on domain-3 of uPAR. Specifically, point mutation of S245 or H249 resulted in inhibition of the association of uPAR and integrin-a5b1. 16, 17 This allows for selective disruption of the complex, a concept that was verified by using a peptide comprising the residues 243-251 of uPAR (TASMCQHAH) that contains both S245 and H249. The peptide efficiently blocked VEGF-induced internalization of the fibronectin receptor in vitro and angiogenesis in vivo. The interaction site between uPAR and integrin a5b1 fulfils several criteria of a candidate drug binding site: (i) it is readily accessible, because it is on the extracellular surface, thus obviating the cell membrane as a permeation barrier. (ii) It allows for discrimination because it can be specifically targeted. (iii) There is no major toxicity that can be a priori anticipated. The absence of uPAR allows for the development of a viable animal 24 but it interferes with VEGF-induced angiogenesis. Our results therefore provide a proof-of-principle that the interface of uPAR and integrin a5b1 may represent a site to be targeted for anti-angiogenic therapy.
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